Autonomix Medical Inc Dossier - Source-backed chat

Autonomix Medical Inc

AMIXNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)-0.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.83Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $7.5M

Shares Outstanding 2M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Autonomix Medical, Inc. is a development-stage medical device company advancing a novel catheter-based "sense, treat, verify" platform designed to map and ablate peripheral nerves. While early clinical data for pancreatic cancer pain mitigation is highly promising, the company faces acute going concern risks with a cash runway extending only into Q4 2026. A Hold rating is recommended pending successful capital raises and FDA IDE clearance for U.S. clinical trials.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$42.00

Mean target$58.80

High · most bullish analyst$75.60

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1020%

The company fails to secure additional funding, leading to severe liquidity constraints that halt clinical development. Regulatory delays or negative safety signals in upcoming trials further impair the platform's viability, resulting in substantial or complete loss of capital for shareholders.

Base CaseCentral scenario

$42.0055%

Autonomix executes its 1-for-21 reverse stock split to maintain Nasdaq listing compliance and raises incremental capital through its ATM program or Lincoln Park equity line. U.S. clinical trials are initiated with slight delays, keeping the company on track for regulatory milestones but with ongoing dilution to existing shareholders.

Bull CaseUpside scenario

$2.0025%

The company successfully secures $30–$36 million in non-dilutive or highly favorable financing, obtains FDA IDE clearance, and initiates its U.S. multicenter clinical trial by late 2026. Positive clinical outcomes accelerate the path to FDA De Novo approval by 2028, unlocking a multi-billion dollar market across visceral cancer pain, hypertension, and cardiology.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class platform technology combining ultra-high sensitivity microchip sensing with RF ablation for real-time procedural validation.
Strong proof-of-concept clinical data showing rapid, durable pain reduction and opioid elimination in pancreatic cancer patients.
Robust intellectual property portfolio with over 120 patents issued or pending extending into the late 2030s.

Key Investment Risks

Substantial doubt regarding the company's ability to continue as a going concern due to a limited cash runway into Q4 2026.
High regulatory and clinical execution risks associated with the FDA De Novo approval pathway targeted for 2028.
Potential for significant equity dilution from future capital raises and outstanding warrant exercises.

Thesis Invalidation Triggers

Failure to obtain FDA IDE clearance for U.S. clinical trials by early 2027.
Inability to secure additional financing before the exhaustion of current cash resources in Q4 2026.
Delisting from the Nasdaq Capital Market due to non-compliance with listing rules.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.